Olema reports Q3 net loss $21.5M, cash $276.9M; OPERA-01 Phase 3 on track

Olema Pharmaceuticals, Inc.

2023-Q3 EPS reported -$1.66

Net loss $21.5M vs $22.7M YoY; cash, equivalents and marketable securities $276.9M.
R&D expenses $19.5M GAAP ($16.7M non-GAAP) as Phase 3 palazestrant trial advances.
OPERA-01 Phase 3 monotherapy trial site activation ongoing, first patient expected Q4 2023.
New palazestrant combination data with CDK4/6 inhibitors to be presented at SABCS Dec 2023.
Appointed Scott Garland to board; completed financing up to $180M (equity + credit facility).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Olema Pharmaceuticals, Inc. reported quarter ended September 30, 2023 results: net income $21.5 million.

Period: quarter ended September 30, 2023
Net income: $21.5 million
Result: reported results

Exact text from the filing

Net loss for the quarter ended September 30, 2023, was $21.5 million

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Olema Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-017991

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.